{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:17Z","timestamp":1791352217190,"version":"4.3.1"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopy might be the initial or dominant manifestation in patients with inborn errors of immunity (IEIs). Biologics and Janus kinase (JAK) inhibitors have emerged as targeted options for atopic disorders in IEIs refractory to conventional treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of PubMed, Web of Science, and Scopus for human studies reporting biologics or JAK inhibitors used specifically to treat atopic manifestations in IEIs. Data on genotypes, clinical phenotypes, treatments, outcomes, adverse events, and laboratory changes were extracted and synthesized. The databases were last searched in April 2026. Study quality was appraised with the Joanna Briggs Institute checklists and the certainty of evidence was rated following GRADE principles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-one studies comprising 172 patients were included. The most common IEIs were STAT3 loss-of-function (LOF) disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952, 30.2%), Netherton syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932, 18.6%), and DOCK8 deficiency (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919, 11.0%). Dupilumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009120, 69.8%) was the most frequently reported agent, followed by JAK inhibitors (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921, 12.2%) and omalizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916, 9.3%). A complete or major clinical response was described in most published patients treated with dupilumab, together with improvement in skin disease in some patients. Omalizumab was also associated with a favorable outcome in atopic dermatitis and asthma, with steroid-sparing effects and few reported adverse events. Responses to JAK inhibitors were most often described in patients with JAK-STAT pathway defects, although adverse events such as anemia were reported in some cases. All proportions are descriptive frequencies among published patients with available outcome information and are not estimates of treatment effectiveness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Published case reports and small series suggest that biologics and JAK inhibitors may provide clinically meaningful control of selected atopic or atopic-like manifestations in some patients with IEIs. Dupilumab has the largest published experience, while JAK inhibitors may be particularly relevant when the underlying disorder involves JAK-STAT pathway activation. Due to the lack of evidence, treatment should remain individualized, genotype-informed, and accompanied by careful infection surveillance and longitudinal outcome assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1867183","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:35Z","timestamp":1791348815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics and JAK inhibitors for atopic manifestations in inborn errors of immunity: a systematic review"],"prefix":"10.3389","volume":"7","author":[{"given":"Mahnaz","family":"Jamee","sequence":"first","affiliation":[{"name":"Human Immune Disorders Laboratory, Garvan Institute of Medical Research","place":["Sydney, NSW, Australia"]},{"name":"St Vincent\u2019s Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roba Maher","family":"Al-Gaweesh","sequence":"additional","affiliation":[{"name":"Pediatric Allergy, Immunology and Rheumatology Unit, Children\u2019s Hospital, Ain-Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Hajialigol","sequence":"additional","affiliation":[{"name":"Student Research Committee, Alborz University of Medical Sciences","place":["Karaj, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Gouda","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Pediatric Allergy, Immunology and Rheumatology Unit, Children\u2019s Hospital, Ain-Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Tirandazi","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Yazd University","place":["Yazd, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Alangari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"El-Owaidy","sequence":"additional","affiliation":[{"name":"Pediatric Allergy, Immunology and Rheumatology Unit, Children\u2019s Hospital, Ain-Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e20250002","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Bousfiha","year":"2025","journal-title":"J Hum Immun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/pai.13510","article-title":"Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity","volume":"32","author":"Azizi","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaci.2021.04.015","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1666600","DOI":"10.3389\/fimmu.2025.1666600","article-title":"Allergic manifestations in inborn errors of immunity: a systematic scoping review","volume":"16","author":"Marbet","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12865-025-00758-9","article-title":"The prevalence of allergic manifestations in inborn errors of immunity: a retrospective cohort study","volume":"26","author":"Esmaeilzadeh","year":"2025","journal-title":"BMC Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jaip.2025.04.014","article-title":"Dominant-negative versus gain-of-function STAT3 defects: a systematic review on epidemiological, clinical, immunological, and molecular aspects","volume":"13","author":"Hajialigol","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.coi.2025.102538","article-title":"Primary atopic disorders: inborn errors of immunity causing severe allergic disease","volume":"94","author":"Vaseghi-Shanjani","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.jaip.2022.04.001","article-title":"Atopy as immune dysregulation: offender genes and targets","volume":"10","author":"Vaseghi-Shanjani","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.waojou.2022.100657","article-title":"Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: a worldwide study","volume":"15","author":"El-Sayed","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1159\/000516596","article-title":"The prevalence of atopic manifestations in 313 Iranian patients with inborn errors of immunity","volume":"182","author":"Ghaini","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12026-025-09708-4","article-title":"Atopic dermatitis in inborn errors of immunity: at the interface of immunodeficiency and immune dysregulation","volume":"73","author":"Szczawi\u0144ska-Pop\u0142onyk","year":"2025","journal-title":"Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20250137","DOI":"10.70962\/jhi.20250137","article-title":"How I treat: infections and inborn errors of immunity\u2014prevention, diagnosis, and treatment","volume":"2","author":"Freeman","year":"2025","journal-title":"J Hum Immun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1129249","DOI":"10.3389\/fped.2023.1129249","article-title":"Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement","volume":"11","author":"Giancotta","year":"2023","journal-title":"Front Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/ACI.0000000000000943","article-title":"Atopic manifestations of inborn errors of immunity","volume":"23","author":"Sams","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaip.2022.12.012","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"11","author":"Jin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","article-title":"Chapter 7: systematic reviews of etiology and risk","volume-title":"JBI Manual for Evidence Synthesis","author":"Moola","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10875-025-01979-8","article-title":"Pediatric IPEX-associated dermatitis responds to dupilumab: evidence from skin transcriptomics and immune profiling","volume":"46","author":"Yang","year":"2026","journal-title":"J Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41390-025-03941-1","article-title":"Dupilumab successfully controlled eczema in wiskott-aldrich syndrome over 52 weeks","volume":"98","author":"Zhu","year":"2025","journal-title":"Pediatr Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10875-024-01837-z","article-title":"Dupilumab in a 9-week-old with netherton syndrome leads to deep symptom control","volume":"45","author":"Vollmuth","year":"2024","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/jcia.2025.13813","article-title":"Case report: atopic dermatitis-like skin manifestations in hypohidrotic ectodermal dysplasia caused by a novel splice site mutation of the EDA gene successfully treated with dupilumab","volume":"8","author":"Uchiyama","year":"2025","journal-title":"J Cutan Immunol Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2024.1507494","article-title":"Case report: advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency","volume":"15","author":"Trombello","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.jacig.2025.100494","article-title":"Stat6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment","volume":"4","author":"Samra","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/pde.15874","article-title":"Rubinstein-taybi syndrome with severe eczema, recurrent infections, and hyper IgE profile responsive to dupilumab treatment","volume":"42","author":"Nanda","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.jacig.2025.100508","article-title":"Successful management of netherton syndrome using IVIG and dupilumab: a case report","volume":"4","author":"Johar","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2576575","DOI":"10.1080\/09546634.2025.2576575","article-title":"Netherton syndrome: effect on ichthyosis linearis circumflexa with dupilumab","volume":"36","author":"Chu","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1111\/exd.70113","article-title":"Blocking of IL-4\/IL-13 signalling with dupilumab results in restoration of serum and cutaneous abnormalities in netherton syndrome","volume":"34","author":"Blunder","year":"2025","journal-title":"Exp Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1715919","DOI":"10.3389\/fimmu.2025.1715919","article-title":"Dupilumab for atopic manifestations in pediatric patients with inborn errors of immunity: efficacy and safety in a genetically diverse cohort","volume":"16","author":"Alsediq","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/pde.15780","article-title":"Improvement in atopic dermatitis and recurrent infection with dupilumab in children with distinct genetic types of hyper-IgE syndrome: a case series and literature review","volume":"42","author":"Dick","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jdcr.2025.06.060","article-title":"Use of dupilumab in eczematous eruptions following hematopoietic cell transplantation","volume":"65","author":"Dick","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e7614","DOI":"10.1002\/ccr3.7614","article-title":"Hyper IgE syndrome-related disease treated with dupilumab: a case report","volume":"11","author":"Kao","year":"2023","journal-title":"Clin Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"646997","DOI":"10.3389\/fped.2021.646997","article-title":"Case report: dupilumab successfully controls severe eczema in a child with elevated IgE levels and recurrent skin infections","volume":"9","author":"Joshi","year":"2021","journal-title":"Front Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e14215","DOI":"10.1111\/pai.14215","article-title":"Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity","volume":"35","author":"Zangari","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e14073","DOI":"10.1111\/pai.14073","article-title":"Clinical, immunological, and genetic description of a Mexican cohort of patients with DOCK8 deficiency","volume":"35","author":"Liquidano-Perez","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5415\/apallergy.0000000000000121","article-title":"The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis","volume":"14","author":"Li","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/pde.15453","article-title":"Prurigo-like atopic dermatitis in a child with CARD11-associated severe combined immunodeficiency successfully treated with dupilumab","volume":"41","author":"Gualdi","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdcr.2024.04.003","article-title":"Dupilumab improved atopic dermatitis without aggravating tuberculous eosinophilic pleural effusion in hyperimmunoglobulin-E syndrome","volume":"48","author":"Chokevittaya","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/pde.15397","article-title":"Severe eczema in wiskott-aldrich syndrome-related disorder successfully treated with dupilumab","volume":"41","author":"Alzahrani","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e20221755","DOI":"10.1084\/jem.20221755","article-title":"Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease","volume":"220","author":"Sharma","year":"2023","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e43360","DOI":"10.7759\/cureus.43360","article-title":"Efficacy of dupilumab in treating atopic dermatitis with recurrent eczema herpeticum in a patient with DOCK8-deficiency hyper-IgE syndrome: a case report","volume":"15","author":"Johar","year":"2023","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/jdv.18504","article-title":"Severe atopic dermatitis in a patient with loeys-dietz syndrome treated with dupilumab","volume":"37","author":"Gkalpakiotis","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.995304","article-title":"Case report: dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis","volume":"13","author":"Caruso","year":"2023","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jacig.2022.08.004","article-title":"Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: a role of type 2 inflammation?","volume":"2","author":"Arruda","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology: Global"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1054422","DOI":"10.3389\/fimmu.2022.1054422","article-title":"Dupilumab improves clinical symptoms in children with netherton syndrome by suppressing Th2-mediated inflammation","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1111\/jdv.17889","article-title":"Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome","volume":"36","author":"Wang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaip.2021.08.042","article-title":"Relieving job: dupilumab in autosomal dominant STAT3 hyper-IgE syndrome","volume":"10","author":"Staudacher","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1044933","DOI":"10.3389\/fimmu.2022.1044933","article-title":"Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: a single center experience","volume":"13","author":"Shamriz","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"878989","DOI":"10.3389\/fimmu.2022.878989","article-title":"Hyper-IgE and carcinoma in CADINS disease","volume":"13","author":"Pietzsch","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/pde.15072","article-title":"Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab","volume":"39","author":"Nihal","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13770","DOI":"10.1111\/pai.13770","article-title":"Remission of eczema and recovery of Th1 polarization following treatment with dupilumab in STAT3 hyper IgE syndrome","volume":"33","author":"Matucci-Cerinic","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/children9030310","article-title":"Dupilumab improves pruritus in netherton syndrome: a case study","volume":"9","author":"Inaba","year":"2022","journal-title":"Children (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jdermsci.2021.03.003","article-title":"Successful dupilumab treatment for ichthyotic and atopic features of netherton syndrome","volume":"102","author":"Murase","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.16883","article-title":"Response to dupilumab in two children with netherton syndrome: improvement of pruritus and scaling","volume":"35","author":"S\u00fc\u00dfmuth","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/1346-8138.15955","article-title":"Treatment options for DOCK8 deficiency-related severe dermatitis","volume":"48","author":"Ollech","year":"2021","journal-title":"J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/pde.14717","article-title":"Generalized eczematous dermatitis and pruritus responsive to dupilumab in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome","volume":"38","author":"Maher","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2021050351","DOI":"10.1542\/peds.2021-050351","article-title":"Dupilumab for STAT3-hyper-IgE syndrome with refractory intestinal complication","volume":"148","author":"Lu","year":"2021","journal-title":"Pediatrics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1016\/j.jaip.2021.06.049","article-title":"Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome","volume":"9","author":"Dixit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ced.14686","article-title":"Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant","volume":"46","author":"Charvet","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"108452","DOI":"10.1016\/j.clim.2020.108452","article-title":"Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome","volume":"215","author":"Sogkas","year":"2020","journal-title":"Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s10875-020-00751-4","article-title":"Efficacy of dupilumab for controlling severe atopic dermatitis in a patient with hyper-IgE syndrome","volume":"40","author":"L\u00e9vy","year":"2020","journal-title":"J Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/ced.14317","article-title":"Successful treatment with dupilumab of an adult with netherton syndrome","volume":"45","author":"Andreasen","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10875-023-01636-y","article-title":"Management of atopy with dupilumab and omalizumab in CADINS disease","volume":"44","author":"Diaz-Cabrera","year":"2024","journal-title":"J Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e14041","DOI":"10.1111\/pai.14041","article-title":"Dominant-negative CARD11 loss-of-function variant presenting with hypereosinophilic syndrome","volume":"34","author":"Wilson","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaad.2024.09.029","article-title":"Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study","volume":"92","author":"Guillemin","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaip.2022.01.011","article-title":"Treatment of STAT3-deficient hyper-immunoglobulin E syndrome with monoclonal antibodies targeting allergic inflammation","volume":"10","author":"James","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaci.2026.04.012","article-title":"Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: single-center cohort analysis","volume":"158","author":"Freeman","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.21037\/tp-2025-379","article-title":"Efficacy of omalizumab in the treatment of STAT3 loss-of-function mutations associated with autosomal dominant hyperimmunoglobulin E syndrome\u2014a case report","volume":"14","author":"Li","year":"2025","journal-title":"Transl Pediatr"},{"key":"B68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.25259\/IJDVL_348_2023","article-title":"Omalizumab and dupilumab for the treatment of autosomal-recessive DOCK8 hyper-IgE syndrome","volume":"91","author":"Guo","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/pde.15400","article-title":"Stk4 deficiency and epidermodysplasia verruciformis-like lesions: a case report","volume":"41","author":"Gutierrez-Marin","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cia2.12273","article-title":"Autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency: an adjunctive role for omalizumab","volume":"5","author":"Nguyen","year":"2022","journal-title":"J Cutan Immunol Allergy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"835257","DOI":"10.3389\/fmed.2022.835257","article-title":"Omalizumab for STAT3 hyper-IgE syndromes in adulthood: a case report and literature review","volume":"9","author":"Lan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/ced.15119","article-title":"Atypical wiskott-aldrich syndrome without thrombocytopenia partially responding to omalizumab therapy","volume":"47","author":"Gupta","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5114\/ceji.2020.101269","article-title":"Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome","volume":"45","author":"Jesenak","year":"2021","journal-title":"Cent Eur J Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.15574\/SP.2020.105.63","article-title":"Hyper IgE syndrome associated with novel DOCK8 heterozygous mutation: \u0430 case report","author":"Osypchuk","year":"2020","journal-title":"Modern Pediatrics Ukraine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10875-019-00731-3","article-title":"A germline mutation in the C2 domain of PLC\u03b32 associated with gain-of-function expands the phenotype for PLCG2-related diseases","volume":"40","author":"Novice","year":"2020","journal-title":"J Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.18176\/jiaci.0469","article-title":"Omalizumab in the treatment of hyper-IgE syndrome: 2 case reports","volume":"30","author":"Gomes","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/08923973.2015.1115518","article-title":"A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e70039","DOI":"10.1111\/pai.70039","article-title":"Systemic JAK inhibitors for treatment of cutaneous manifestations in a patient with SPINK5 variants: a case report and review of the literature","volume":"36","author":"Wilson","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"B79","first-page":"266","article-title":"Treatment of netherton syndrome in pediatrics with upadacitinib","volume":"31","author":"Sun","year":"2025","journal-title":"Altern Ther Health Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.jaci.2025.09.012","article-title":"Jak1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease","volume":"156","author":"Fujita","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/ijd.17183","article-title":"Abrocitinib: a useful treatment option for CARD14-mutation-associated atopic dermatitis","volume":"63","author":"Liu","year":"2024","journal-title":"Int J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e20232387","DOI":"10.1084\/jem.20232387","article-title":"Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis","volume":"221","author":"Horesh","year":"2024","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamadermatol.2023.0561","article-title":"Treatment of netherton syndrome with abrocitinib","volume":"159","author":"Zheng","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaci.2023.06.004","article-title":"Successful treatment of JAK1-associated inflammatory disease","volume":"152","author":"Fayand","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2023.01.023","article-title":"Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6","volume":"152","author":"Baris","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e150849","DOI":"10.1172\/jci.insight.150849","article-title":"Human JAK1 gain of function causes dysregulated myelopoeisis and severe allergic inflammation","volume":"7","author":"Biggs","year":"2022","journal-title":"JCI Insight"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaip.2020.11.050","article-title":"Jak inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease","volume":"9","author":"Eisenberg","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B88","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","article-title":"Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function","volume":"53","author":"Gruber","year":"2020","journal-title":"Immunity"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"Jak1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.chest.2020.11.042","article-title":"Benralizumab for prednisone-dependent eosinophilic asthma associated with novel STAT3 loss of function mutation","volume":"159","author":"Adatia","year":"2021","journal-title":"Chest"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/ajd.14234","article-title":"Successful infliximab treatment in siblings with netherton syndrome: unveiling a novel SPINK5 gene variant and literature review","volume":"65","author":"Salici","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/pde.14590","article-title":"Infliximab therapy in an infant with netherton syndrome","volume":"38","author":"Cicek","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ajd.13880","article-title":"Secukinumab use in the treatment of netherton\u2019s syndrome","volume":"63","author":"Gan","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab therapy for netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","article-title":"Successful use of secukinumab in netherton syndrome","volume":"6","author":"Blanchard","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B96","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/ijd.70147","article-title":"Successful use of tralokinumab in a pediatric patient with STAT3 hyper-IgE syndrome following dupilumab-associated conjunctivitis","volume":"65","author":"Camino-Salvador","year":"2025","journal-title":"Int J Dermatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.18892","article-title":"Successful treatment of netherton syndrome with ustekinumab in a 15-year-old girl","volume":"183","author":"Volc","year":"2020","journal-title":"Br J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijd.17707","article-title":"Type 2 inflammation and its role in dermatologic diseases","volume":"64","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"B101","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fped.2019.00353","article-title":"Inborn errors of immunity with immune dysregulation: from bench to bedside","author":"Delmonte","year":"2019","journal-title":"Front Pediatr"},{"key":"B103","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaci.2024.05.007","article-title":"TH2-driven manifestations of inborn errors of immunity","volume":"154","author":"James","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jtct.2025.08.021","article-title":"Dupilumab for the treatment of cutaneous graft-versus-host disease: a systematic review and individual patient data meta-analysis","volume":"31","author":"Consonni","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B105","year":"2026"},{"key":"B106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B107","year":"2026"},{"key":"B108","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"218","DOI":"10.37349\/ei.2024.00138","article-title":"Targeted treatments for immune dysregulation in inborn errors of immunity","volume":"4","author":"Makkoukdji","year":"2024","journal-title":"Explor Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1694688","DOI":"10.3389\/fmed.2025.1694688","article-title":"Association between oral JAK-1 inhibitors and infection risks in atopic dermatitis: a retrospective analysis of the FAERS database","volume":"12","author":"Tang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B112","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaci.2026.05.005","article-title":"Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: international consensus statement on behalf of the European society for immunodeficiencies\/European society for blood and marrow transplantation\u2013inborn errors working party and ERN-RITA","volume":"158","author":"Olbrich","year":"2026","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1867183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:37Z","timestamp":1791348817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1867183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":112,"alternative-id":["10.3389\/falgy.2026.1867183"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1867183","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1867183"}}